New algorithm aims to catch ovarian damage early in young cancer survivors
NCT ID NCT05048654
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study was designed to see if a new monitoring algorithm could detect early signs of ovarian damage in women and girls who had cancer treatment. Researchers planned to compare a group using the new algorithm with a group that received standard care. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Jun 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Study participants will be pre- and post-pubertal females 8 years and older greater seen at the University of Colorado Anschutz Pavilion and/or Children's Hospital Colorado who have received gonadotoxic chemotherapy; radiation; or surgical excision of a reproductive organ for malignancy. The anticipated study population for Group B will be approximately 3,338 per year for five years for an projected total of 16, 690. Group A will have an anticipated study population of 3,338 per year for three years for an projected total of 10,014. For Groups A and B that is a grand total of 26,704.
- Ages
-
8 to 39 years
- Sex
-
Female participants only
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * · Female patients ages 8 - 39 years of age * Seen in CHCO or AMC outpatient clinics for any of the following reasons: * At risk for fertility problems (Z91.89) * Encounter for fertility preservation counseling (Z31.62) * Primary ovarian insufficiency * Premature ovarian failure/premature menopause * Diminished ovarian reserve * At least 12 months post-completion of chemotherapy and/or radiation * History of a fertility-threatening diagnosis receiving chemotherapy; radiation; or surgery to the reproductive organs for malignancy, including but not limited to: * Any type of cancer/malignancy * Rheumatoid arthritis * Systemic lupus erythematosus * Aplastic anemia * Fanconi anemia * Diamond-Blackfan syndrome * Hurler syndrome * Other autoimmune conditions Exclusion Criteria: * Disorders of sexual development (i.e., gonadal dysgenesis, Turner syndrome/mosaicism, etc.) * History of bilateral oophorectomy * Transgender patients not receiving chemotherapy; radiation; or surgery to the reproductive organs for malignancy * Inability to consent/assent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aplastic anemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Ear-Zapping device may quiet lupus pain and fatigue
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success